CN102449172A - 施用针对登革病毒的疫苗的组合物和方法 - Google Patents

施用针对登革病毒的疫苗的组合物和方法 Download PDF

Info

Publication number
CN102449172A
CN102449172A CN2010800241489A CN201080024148A CN102449172A CN 102449172 A CN102449172 A CN 102449172A CN 2010800241489 A CN2010800241489 A CN 2010800241489A CN 201080024148 A CN201080024148 A CN 201080024148A CN 102449172 A CN102449172 A CN 102449172A
Authority
CN
China
Prior art keywords
dengue virus
composition
subject
vaccine
dengue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800241489A
Other languages
English (en)
Chinese (zh)
Inventor
D·T·斯汀奇科姆
J·E·奥索瑞罗
C·D·帕提度斯
J·N·布瑞沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inviragen Inc
Original Assignee
Iveragen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43220488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102449172(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iveragen filed Critical Iveragen
Priority to CN201711026301.1A priority Critical patent/CN107913406A/zh
Publication of CN102449172A publication Critical patent/CN102449172A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800241489A 2009-06-01 2010-05-28 施用针对登革病毒的疫苗的组合物和方法 Pending CN102449172A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711026301.1A CN107913406A (zh) 2009-06-01 2010-05-28 施用针对登革病毒的疫苗的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18302009P 2009-06-01 2009-06-01
US61/183,020 2009-06-01
PCT/US2010/036726 WO2010141386A1 (en) 2009-06-01 2010-05-28 Compositions and methods for administration of vaccines against dengue virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711026301.1A Division CN107913406A (zh) 2009-06-01 2010-05-28 施用针对登革病毒的疫苗的组合物和方法

Publications (1)

Publication Number Publication Date
CN102449172A true CN102449172A (zh) 2012-05-09

Family

ID=43220488

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800241489A Pending CN102449172A (zh) 2009-06-01 2010-05-28 施用针对登革病毒的疫苗的组合物和方法
CN201711026301.1A Pending CN107913406A (zh) 2009-06-01 2010-05-28 施用针对登革病毒的疫苗的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711026301.1A Pending CN107913406A (zh) 2009-06-01 2010-05-28 施用针对登革病毒的疫苗的组合物和方法

Country Status (17)

Country Link
US (2) US9211323B2 (enExample)
EP (1) EP2438198A4 (enExample)
JP (2) JP5848243B2 (enExample)
KR (1) KR101876304B1 (enExample)
CN (2) CN102449172A (enExample)
AU (3) AU2010256845B2 (enExample)
CA (1) CA2763944A1 (enExample)
CL (1) CL2011003043A1 (enExample)
CO (1) CO6470882A2 (enExample)
CU (1) CU20110219A7 (enExample)
IL (2) IL216706A0 (enExample)
MX (1) MX343172B (enExample)
MY (1) MY184428A (enExample)
NZ (2) NZ618158A (enExample)
PH (1) PH12016502431A1 (enExample)
SG (1) SG176299A1 (enExample)
WO (1) WO2010141386A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) * 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
WO2014093182A1 (en) * 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
KR102611235B1 (ko) 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
JP7382634B2 (ja) 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1431913A (zh) * 2000-05-30 2003-07-23 艾文蒂斯巴斯德公司 疫苗组合物
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2008022196A2 (en) * 2006-08-15 2008-02-21 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health Andhuman Services, The Development of dengue virus vaccine components
US20080131460A1 (en) * 2006-12-01 2008-06-05 Sanofi Pasteur Sa Method of Immunization Against the 4 Serotypes of Dengue Fever
CN101287490A (zh) * 2005-08-10 2008-10-15 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE310824T1 (de) * 1991-09-19 2005-12-15 Chimäre und/oder wachstumsgehemmte flaviviren
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
DE60041250D1 (de) * 1999-03-26 2009-02-12 Us Army Multivalenter dengue-virus impfstoff
WO2001060847A2 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
NZ584079A (en) * 2004-10-20 2011-10-28 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US7618393B2 (en) * 2005-05-03 2009-11-17 Pharmajet, Inc. Needle-less injector and method of fluid delivery
MX2007015872A (es) * 2005-06-17 2008-04-21 Sanofi Pasteur Cepa atenuada del serotipo 2 del dengue.
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2008085288A1 (en) * 2007-01-11 2008-07-17 Sealed Air Corporation (Us) Method of shaping insulation
WO2008157136A1 (en) 2007-06-14 2008-12-24 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Chimeric sle/dengue type 4 antigenic viruses
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1431913A (zh) * 2000-05-30 2003-07-23 艾文蒂斯巴斯德公司 疫苗组合物
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CN101287490A (zh) * 2005-08-10 2008-10-15 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
WO2008022196A2 (en) * 2006-08-15 2008-02-21 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health Andhuman Services, The Development of dengue virus vaccine components
US20080131460A1 (en) * 2006-12-01 2008-06-05 Sanofi Pasteur Sa Method of Immunization Against the 4 Serotypes of Dengue Fever

Also Published As

Publication number Publication date
NZ618158A (en) 2015-05-29
JP2012528794A (ja) 2012-11-15
AU2010256845A1 (en) 2011-12-22
EP2438198A4 (en) 2014-05-14
IL243204A0 (en) 2016-02-29
SG176299A1 (en) 2012-01-30
CU20110219A7 (es) 2012-06-21
MX2011012807A (es) 2012-01-30
US20100303860A1 (en) 2010-12-02
CO6470882A2 (es) 2012-06-29
KR20120027396A (ko) 2012-03-21
PH12016502431A1 (en) 2019-02-11
US10010600B2 (en) 2018-07-03
EP2438198A1 (en) 2012-04-11
KR101876304B1 (ko) 2018-07-10
MY184428A (en) 2021-04-01
IL216706A0 (en) 2012-02-29
AU2019200212A1 (en) 2019-01-31
MX343172B (es) 2016-10-26
NZ597000A (en) 2014-07-25
AU2016277660A1 (en) 2017-01-12
AU2010256845B2 (en) 2016-09-22
US20160129102A1 (en) 2016-05-12
JP5848243B2 (ja) 2016-01-27
US9211323B2 (en) 2015-12-15
CA2763944A1 (en) 2010-12-09
CL2011003043A1 (es) 2012-07-20
CN107913406A (zh) 2018-04-17
WO2010141386A1 (en) 2010-12-09
JP2016033151A (ja) 2016-03-10

Similar Documents

Publication Publication Date Title
JP5848243B2 (ja) デングウイルスに対する免疫原性組成物
US11975067B2 (en) Coronavirus disease (COVID-19) vaccine
US8968996B2 (en) Compositions and methods for rapid immunization against dengue virus
US20090246223A1 (en) Inactivated Chimeric Vaccines and Related Methods of Use
JP2018090618A (ja) デングウイルスに対する免疫原性組成物およびワクチンキット
CN102168088A (zh) T细胞免疫原基因ti及其在口蹄疫蛋白亚单位疫苗和灭活疫苗中的应用
Nielsen et al. DNA vaccines encoding proteins from wild-type and attenuated canine distemper virus protect equally well against wild-type virus challenge
Tsiang Rabies vaccines: a review of progress towards improved efficacy and safety

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150911

Address after: Delaware

Applicant after: INVIRAGEN, INC.

Address before: American Colorado

Applicant before: Inviragen Inc.

RJ01 Rejection of invention patent application after publication

Application publication date: 20120509

RJ01 Rejection of invention patent application after publication